GlassScriptPhysician profile
Karole Lynn Murphy
NPI 1285120287
$5,645.00
in general payments reported to CMS, 2019-2025
46 companies · $86.19 in 2025
The $86.19 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $2,545 · 2023: $1,738 · 2024: $810 · 2025: $86.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.60 |
| Education | $183.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $729.38 | 2021-2024 | Calquence, Tagrisso |
| Incyte Corporation | $458.98 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $372.89 | 2022-2023 | Tukysa, Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $303.85 | 2022-2023 | Imbruvica |
| Astellas Pharma US INC | $293.00 | 2021-2023 | Xospata, Padcev |
| Novartis Pharmaceuticals Corporation | $273.00 | 2022-2025 | |
| Genzyme Corporation | $244.30 | 2022-2023 | |
| Daiichi Sankyo INC. | $200.22 | 2022-2024 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $199.53 | 2022-2024 | Keytruda, Lynparza |
| Pfizer INC. | $187.69 | 2022-2025 | |
| Abbvie INC. | $173.49 | 2023-2024 | |
| Janssen Biotech, INC. | $169.06 | 2022-2024 | Darzalex |
| Genentech USA, INC. | $162.85 | 2022-2024 | Columvi, Polivy, Lunsumio |
| Lilly USA, LLC | $148.66 | 2022-2024 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $144.35 | 2021-2023 | Trodelvy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karole Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.